Study of Canakinumab in Patients With Myelofibrosis
- Conditions
- Interventions
- First Posted Date
- 2022-07-21
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- John Mascarenhas
- Target Recruit Count
- 10
- Registration Number
- NCT05467800
- Locations
- ๐บ๐ธ
Mayo Clinic Arizona, Phoenix, Arizona, United States
๐บ๐ธCedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California, United States
๐บ๐ธMoffitt Cancer Center, Tampa, Florida, United States
Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation
- Conditions
- Interventions
- First Posted Date
- 2020-02-24
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- John Mascarenhas
- Target Recruit Count
- 6
- Registration Number
- NCT04281498
- Locations
- ๐บ๐ธ
Taussig Cancer Center Institute, Cleveland, Ohio, United States
๐บ๐ธMemorial Sloan-Kettering Cancer Center, New York, New York, United States
๐บ๐ธIcahn School of Medicine at Mount Sinai, New York, New York, United States
MPN-RC 118 AVID200 in Myelofibrosis
- Conditions
- Interventions
- First Posted Date
- 2019-03-29
- Last Posted Date
- 2023-02-10
- Lead Sponsor
- John Mascarenhas
- Target Recruit Count
- 21
- Registration Number
- NCT03895112
- Locations
- ๐บ๐ธ
Icahn School of Medicine at Mount Sinai, New York, New York, United States
PD-1 Inhibition in Advanced Myeloproliferative Neoplasms
- Conditions
- Interventions
- First Posted Date
- 2017-02-27
- Last Posted Date
- 2021-06-21
- Lead Sponsor
- John Mascarenhas
- Target Recruit Count
- 10
- Registration Number
- NCT03065400
- Locations
- ๐บ๐ธ
Icahn School of Medicine at Mount Sinai, New York, New York, United States
๐บ๐ธHarvard Medical School Massachusetts General Hospital, Boston, Massachusetts, United States
๐บ๐ธMontefiore Medical Center Division of Hematology, Department of Oncology, Bronx, New York, United States
Open Label Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia
- Conditions
- Interventions
- First Posted Date
- 2015-04-02
- Last Posted Date
- 2019-09-12
- Lead Sponsor
- John Mascarenhas
- Target Recruit Count
- 13
- Registration Number
- NCT02407080
- Locations
- ๐บ๐ธ
Georgetown University Medical Center, Washington, District of Columbia, United States
๐บ๐ธIcahn School of Medicine at Mount Sinai, New York, New York, United States
๐บ๐ธWake Forest University Baptist Medical Center, Winston-Salem, North Carolina, United States
Study of Combination Ruxolitinib and Decitabine Treatment for Accelerated Phase MPN or Post-MPN AML
- Conditions
- Interventions
- First Posted Date
- 2014-03-03
- Last Posted Date
- 2019-02-28
- Lead Sponsor
- John Mascarenhas
- Target Recruit Count
- 49
- Registration Number
- NCT02076191
- Locations
- ๐บ๐ธ
Washington University of St. Louis, Saint Louis, Missouri, United States
๐บ๐ธRoswell Park Cancer Institute, Buffalo, New York, United States
๐บ๐ธIcahn School of Medicine at Mount Sinai, New York, New York, United States
Ruxolitinib Prior to Transplant in Patients With Myelofibrosis
- First Posted Date
- 2013-02-13
- Last Posted Date
- 2019-03-20
- Lead Sponsor
- John Mascarenhas
- Target Recruit Count
- 21
- Registration Number
- NCT01790295
- Locations
- ๐บ๐ธ
Icahn School of Medicine at Mount Sinai, New York, New York, United States
๐บ๐ธEmory Hospital, Atlanta, Georgia, United States
๐บ๐ธNorthwestern University, Robert h. Lurie Comprehensive Cancer Center, Chicago, Illinois, United States
Panobinostat and Ruxolitinib In MyElofibrosis (PRIME Trial)
- First Posted Date
- 2012-09-26
- Last Posted Date
- 2023-10-31
- Lead Sponsor
- John Mascarenhas
- Target Recruit Count
- 15
- Registration Number
- NCT01693601
- Locations
- ๐บ๐ธ
Icahn School of Medicine at Mount Sinai, New York, New York, United States
Anti-TGF-beta Therapy in Patients With Myelofibrosis
- First Posted Date
- 2011-02-08
- Last Posted Date
- 2014-12-08
- Lead Sponsor
- John Mascarenhas
- Target Recruit Count
- 3
- Registration Number
- NCT01291784
- Locations
- ๐บ๐ธ
Icahn School of Medicine at Mount Sinai, New York, New York, United States
Study of Fludarabine Based Conditioning for Allogeneic Stem Cell Transplantation for Myelofibrosis
- First Posted Date
- 2007-12-13
- Last Posted Date
- 2017-05-15
- Lead Sponsor
- John Mascarenhas
- Target Recruit Count
- 66
- Registration Number
- NCT00572897
- Locations
- ๐ฎ๐น
University of Florence, Florence, IL, Italy
๐บ๐ธOhio State Univesity, Columbus, Ohio, United States
๐บ๐ธUniversity of Utah, Salt Lake City, Utah, United States